• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Liminal takes buyout from top shareholder at peach of a price

    12 Jul 2023 //

    FIERCE BIOTECH

    Annexon, Liminal shrink pipelines to focus on possible homeruns

    09 Jan 2023 //

    FIERCE BIOTECH

    Liminal Biosciences to Present at H.C. Wainwright 24th Annual Global Conference

    29 Aug 2022 //

    PRNEWSWIRE

    Liminal BioSciences Announces Termination of Legacy CDMO Contract

    27 Aug 2022 //

    BIOPHARMA APAC

    Liminal BioSciences Announces First Subject Dosed in Phase 1a Trial

    23 May 2022 //

    PRNEWSWIRE

    Ocugen Signs LOI to Acquire Vaccine Manufacturing, R&D Hub in Ontario, Canada

    27 Jan 2022 //

    GLOBENEWSWIRE

    Liminal BioSciences Announces Sale of Priority Review Voucher for USD105M

    09 Aug 2021 //

    PRNEWSWIRE

    Liminal BioSciences Announces Signature of a Share Purchase Agreement

    23 Jun 2021 //

    BIOSPACE

    Liminal BioSciences Provides an Update on Currently Planned Clinical Fezagepras

    28 May 2021 //

    PRNEWSWIRE

    Liminal Announces Closing of Divestiture of Plasma Collection Centers

    21 May 2021 //

    PRNEWSWIRE

    Delic`s Acquisition Target, Complex Biotech Discovery Announces Closing

    17 May 2021 //

    BIOSPACE

    Liminal Enters into Agreement with Kedrion to Divest Its Plasma Collection

    17 May 2021 //

    PRNEWSWIRE

    Liminal Provides Update on Business Strategy and Focus on Small Molecule

    28 Jan 2021 //

    PRNEWSWIRE

    Liminal BioSciences Announces First Subject Dosed in Phase 1 Multiple

    15 Dec 2020 //

    PRNEWSWIRE

    Liminal BioSciences Presents Two Case Histories on Investigational

    07 Dec 2020 //

    PRESS RELEASE

    Liminal BioSciences Announces FDA Extension of Review Period for Ryplazim

    09 Nov 2020 //

    BIOSPACE

    Liminal BioSciences Announces Upcoming Presentations for Ryplazim®

    04 Nov 2020 //

    PRNEWSWIRE

    Liminal BioSciences Provides Update on Progress on BLA for Ryplazim®

    21 Sep 2020 //

    PRNEWSWIRE

    Liminal BioSciences Announces Resubmission of Biologics License Application

    09 Sep 2020 //

    DRUG-DEV

    Liminal resubmits Biologics License Application to U.S. FDA for Ryplazim

    08 Sep 2020 //

    PRNEWSWIRE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.